Establishment of BCWM.1 cell line for Waldenström’s macroglobulinemia with productive in vivo engraftment in SCID-hu mice

Daniel Ditzel Santos\textsuperscript{a,b}, Allen W. Ho\textsuperscript{a,c}, Olivier Tournilhac\textsuperscript{a,b}, Evdoxia Hatjiharissi\textsuperscript{a,b}, Xavier Leleu\textsuperscript{a,b}, Lian Xu\textsuperscript{a}, Pierfrancesco Tassone\textsuperscript{a,c,d}, Paola Neri\textsuperscript{a,c,d}, Zachary R. Hunter\textsuperscript{a}, Mariana A.Z. Chemaly\textsuperscript{a}, Andrew R. Branagan\textsuperscript{a}, Robert J. Manning\textsuperscript{a}, Christopher J. Patterson\textsuperscript{a}, Anne Sophie Moreau\textsuperscript{a,b}, Bryan Ciccarelli\textsuperscript{a}, Sophia Adami\textsuperscript{a,e}, Jitra Kriangkum\textsuperscript{e}, Jeffery L. Kutok\textsuperscript{b}, Yu-Tzu Tai\textsuperscript{a,b}, Jiangwen Zhang\textsuperscript{f}, Linda M. Pilarski\textsuperscript{e}, Kenneth C. Anderson\textsuperscript{b}, Nikhil Munshi\textsuperscript{b,c}, and Steven P. Treon\textsuperscript{a,b}

\textsuperscript{a}Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute. Boston, Mass., USA; \textsuperscript{b}Department of Medicine, Harvard Medical School, Boston, Mass., USA; \textsuperscript{c}VA Boston Healthcare System, Boston, Mass., USA; \textsuperscript{d}University of “Magna Graecia” and Cancer Center, Catanzaro, Italy; \textsuperscript{e}Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada; \textsuperscript{f}FAS Center for Systems Biology, Harvard University, Cambridge Mass., USA

(Received 31 March 2007; revised 23 May 2007; accepted 31 May 2007)

A significant impairment in understanding the biology and advancing therapeutics for Waldenström’s macroglobulinemia (WM) has been the lack of a representative cell line and animal model. We, therefore, report on the establishment of the BCWM.1 cell line, which was derived from the long-term culture of CD19\textsuperscript{+} selected bone marrow lymphoplasmacytic cells isolated from an untreated patient with WM. BCWM.1 cells morphologically resemble lymphoplasmacytic cells (LPC) and propagate in RPMI-1640 medium supplemented with 10\% fetal bovine serum. Phenotypic characterization by flow cytometric analysis demonstrated typical WM LPC characteristics: CD5\textsuperscript{L}, CD10\textsuperscript{L}, CD19\textsuperscript{+}, CD20\textsuperscript{+}, CD23\textsuperscript{+}, CD27\textsuperscript{L}, CD38\textsuperscript{+}, CD138\textsuperscript{+}, CD40\textsuperscript{+}, CD52\textsuperscript{+}, CD70\textsuperscript{+}, clgM\textsuperscript{+}, clG\textsuperscript{+}, clGA\textsuperscript{+}, c\textsuperscript{X}, c\textsuperscript{A}, as well as the survival proteins APRIL and BLYS, and their receptors TACI, BCMA and BAFF-R. Enzyme-linked immunosorbent assay studies demonstrated secretion of IgM\textsubscript{\lambda} and soluble CD27. Karyotypic and multicolor fluorescence in situ hybridization studies did not demonstrate cytogenetic abnormalities. Molecular analysis of BCWM.1 cells confirmed clonality by determination of \textit{IgH} rearrangements. Inoculation of BCWM.1 cells in human bone marrow chips implanted in severe combined immunodeficient-hu mice led to rapid engraftment of tumor cells and serum detection of human IgM\textsubscript{\lambda}, and soluble CD27. These studies support the use of BCWM.1 cells as an appropriate model for the study of WM, which in conjunction with the severe combined immunodeficient-hu mouse model may be used as a convenient model for studies focused on both WM pathogenesis and development of targeted therapies for WM.

Waldenström’s macroglobulinemia (WM) is an incurable B-cell malignancy primarily characterized by bone marrow infiltration with lymphoplasmacytic cells (LPC), along with demonstration of an IgM monoclonal gammapathy [1]. The underlying pathological disorder for WM is considered to be lymphoplasmacytic lymphoma as defined by the Revised European-American Lymphoma and World Health Organization classification systems [2,3]. A strong familial predisposition has been reported in WM, with up to 20\% of patients demonstrating a first-degree relative with WM or a closely related B-cell malignancy [4].

Several studies have been published on cytogenetic findings in WM, with deletions of chromosome 6q21-22...
constituting the most widely reported cytogenetic abnormality. Deletions in 6q21-22 have been observed in half of WM patients, irrespective of familial history, and may help discriminate WM from IgM monoclonal gammapathy of undetermined significance [4–6]. Several candidate tumor suppressor genes in this region are under study, including BLIMP-1, a master regulatory gene implicated in lympho-plasmacytic differentiation and gene downstream of BLIMP-1, including PAX-5, XBP-1, and the XBP-1 splicing protein IRE-1 [7,8]. A consistent finding in the genetic studies of WM has been the absence of IgH region switch rearrangements, a finding that may be used to discern cases of IgM myeloma where IgH region switch rearrangements are a predominant feature [9]. A strong preferential usage of VH3/JH4 gene families, without intraclonal variation and isotype-switched transcripts has also been reported in WM [10,11], suggesting that WM may have originated from a IgM+ and/or IgM+ IgD+ memory B cell.

The phenotype of LPC in WM cell further suggests that the malignant clone is likely to represent a postgerminal center B cell. LPC in WM express cell surface CD19, CD20, CD22, CD52, IgM, IgD, as well as the activation markers CD25, CD38, CD40, and CD70 [12–15]. Variably, WM LPC may also express CD5, CD10, CD23 [16]. Normally CD27 is expressed on the cell surface of memory B cells from which the WM clone is thought to derive. However, in WM, CD27 is heterogeneously expressed, and more often is absent on the cell surface of WM LPC [11,12,14]. In addition, WM LPC widely express the tumor necrosis factor family members B-lymphocyte stimulator protein and a proliferation-inducing ligand (APRIL) as well as their receptors, which may provide growth and survival signals [17–20]. Lastly, WM cells secrete both IgM and soluble CD27 (sCD27), both of which serve as markers of disease burden in WM [19,20]. Importantly, sCD27 may also have an important biological role in WM pathogenesis by inducing the growth and survival factors APRIL and CD40L on mast cells, which are found in increased number in the bone marrow (BM) of patients and support the expansion of WM cells [19–24].

A significant impairment in understanding the biology and advancing therapeutics for WM has been the lack of representative cell lines and an animal model. In this study, we report on the establishment of a cell line that demonstrates typical cytogenetic, morphological, and phenotypic features of WM, and that readily engrafts and provides a representative model of WM disease in severe combined immunodeficient (SCID)-hu mice.

Materials and methods

Case description
In April 2004, a previously untreated female patient presented with complaints of headaches, blurry vision, lethargy, persistent sweating, bilateral hand tingling, nose bleeds, easy bruising, leg cramps, diffuse joint pain, and frequent sinus infections with no concomitant loss of weight. Her social history was unremarkable for cigarette smoking, alcohol use, or occupational exposures. Likewise, her family history was unremarkable for any malignancy or other B-cell disorder. On physical examination, she demonstrated no adrenopathy or hepatosplenomegaly. Laboratory tests demonstrated normocytic anemia, along with a normal white blood and platelet count. Electrolytes and liver function tests were within normal limits. Serum IgM level at time of evaluation was 4430 (normal range, 40–230 mg/dL), and serum viscosity was 2.5 (normal range, 1.4–1.8 CP). Moreover, as is typical of WM, IgG and IgA levels were subnormal at 676 (range, 700–1600 mg/dL) and 26 (range, 70–400 mg/dL), respectively [25]. B2-microglobulin, a prognostic factor in WM, was normal at 1.8 mg/dL [15]. Both antitymelysin-associated glycoprotein and ganglioside M1 antibodies obtained as part of a workup for an IgM-related neuropathy were not present. A bone marrow biopsy demonstrated 5% intertrabecular space involvement with lympho-plasmacytic cells consistent with the Revised European-American Lymphoma/World Health Organization pathological diagnosis of lymphoplasmacytic lymphoma [2,3]. By flow cytometric analysis, LC coexpressed CD19, CD20, and CD52, and were negative for CD5, CD10, and CD11c. Serological studies were unremarkable for hepatitis B, C, and HIV, but demonstrated remote infection with Epstein-Barr virus.

Isolation of BCWM.1 WM cells
A BM aspirate was obtained for these studies following informed consent, and with the approval of our Institutional Review Board. The patient was newly diagnosed and untreated at time the BM aspirate was obtained. Mononuclear cells from the BM aspirate were isolated by density-gradient centrifugation using Ficoll-Paque Plus-1070 (Pharmacia Biotech, Piscataway, NJ, USA). LPC immunoselection was performed using a CD19+ cell isolation kit (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer’s instructions. Following CD19+ isolation, >90% of cells coexpressed CD20. LPCs were then cultured in Stem Pro 34 serum-free media (Life Technologies, Grand Island, NY, USA), supplemented with 2 mM l-glutamine (Mediatech, Cellgro, AK, USA), 100 U/mL penicillin, 10 μg streptomycin (Mediatech), and stem cell factor at 100 ng/mL (Amgen, Thousand Oaks, CA, USA), given that 96% of cells expressed CD117. Expanded cells were doubled every 3 days for the first 4 months of culture. At 4 months, cells were subcultured in RPMI-1640 plus 10% heat-inactivated fetal bovine serum, with 2 mM l-glutamine (Mediatech), 100 U/mL penicillin and 10 μg streptomycin (Mediatech), and stem cell factor at 100 ng/mL (Amgen, Thousand Oaks, CA, USA), demonstrating 5% intertrabecular space involvement with lympho-plasmacytic cells consistent with the Revised European-American Lymphoma/World Health Organization pathological diagnosis of lymphoplasmacytic lymphoma [2,3]. By flow cytometric analysis, LC coexpressed CD19, CD20, and CD52, and were negative for CD5, CD10, and CD11c. Serological studies were unremarkable for hepatitis B, C, and HIV, but demonstrated remote infection with Epstein-Barr virus.

Morphological characterization of BCWM.1 cells
Morphological assessment was performed by a cytopathologist following Giemsa staining of cytospins. For electron microscopic analysis, cells were fixed in 2% paraformaldehyde/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, at a pH of 7.4 for 1 hour at room temperature; postfixed in 1% osmium tetroxide/1.5% potassium ferrocyanide in water for 30 minutes; and then
stained in 1% uranyl acetate in maleate buffer pH 5.2 for 30 minutes at room temperature. After dehydration in graduated ethanols (70%, 95%, and 2× 100%), cells were removed from the dish, placed in propylene oxide, and centrifuged at 3000 rpm for 3 minutes. Pellets were suspended in a 1:1 mixture of propylene oxide and Epon (TAAB Epon, Marivac Ltd, Nova Scotia, Canada) for 2 hours at room temperature, transferred to embedding molds filled with pure TAAB Epon, and polymerized for 48 hours at 60°C. Ultrathin sections (80–90 nm) were mounted on copper grids, stained with 2% uranyl acetate in acetone followed by 0.2% lead citrate, and then examined in a JEOL 1200EX transmission electron microscope, as described previously [12].

Phenotypic characterization of BCWM.1 cells
Multicolor flow cytometric analysis was performed using FC500 Analyzer. Staining patterns for all antibodies used were compared to their respective isotype control. The following antibodies were used: CD5, CD9, CD10, CD11a, CD11c, CD19, CD20, CD22, CD25, CD23, CD30, CD34, CD38, CD66b, CD80, IgM, IgG, IgD, CD138, FMC7, and CD40, all conjugated to PC5 (BD Biosciences, San Jose, CA, USA); CD4, CD8, CD14, CD16, CD27, CD56 (Beckman Coulter, Miami, FL, USA), CD70 (RDI, Flanders, NJ, USA); CD52 (Serotech Inc., Raleigh, NC, USA), anti-FcεRIα (Upstate, Lake Placid, NY, USA), all conjugated to fluorescein isothiocyanate (Pharmacia); BlyS (eBioscience, San Diego, CA, USA); TACI (R & D Systems, Minneapolis, MN, USA); BCMA (Axxora, San Diego, CA, USA), and BR3 (Genentech BioOncology, Inc., San Francisco, CA, USA), all conjugated to phycoerythrin (Pharmacia); and CD117, conjugated to PerCP-Cy5.5. Antigen expression was deemed positive if ≥20% of cells demonstrated specific binding. Intracellular staining was also analyzed for immunoglobulins and light chain presence following membrane permeabilization.

Reverse transcriptase polymerase chain reaction analysis for APRIL, BLYS, and their receptors
Total RNA was extracted from 1–5 × 10⁶ LPCs and 0.2–1 × 10⁶ MCs using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The 0.3 μg RNA was reverse transcripted in a 20 μL reaction by oligo-p(dT)₁₅ priming using Superscript III reverse transcriptase according to the protocol provided by Invitrogen. First-strand cDNA was synthesized using Superscript III reverse transcriptase according to the protocol also provided by Invitrogen. Two microliters first-strand cDNA was used as template for PCR amplification. PCR was performed using the PTC-200 DNA EngineThermal Cycler (MJ Research Inc., Waltham, MA, USA). The pool of primers used in these experiments was as follows: BCMA (sense): 5’-TAA CTT CTT CCA GGC TGT TCT-3’; BCMA (antisense): 5’-CAT AGA AAC CAA GGA AGT TTC TAC C-3’; TACI (sense): 5’- TGG GAC TCA GAG TGC C -3’; BLYS (sense): 5’- TCA AGG TGC ATG AGG TCT GAA GCC -3’; BLYS (antisense): 5’- GCT ACA GAC ATG GTG TAA GTA GG 3; APRIL (sense): 5’-CCT TGC TAC CCC ACT CTT G-3’; APRIL (antisense): 5’-ACA CTC AGA AGA AAC AGT C 3’; glyceraldehyde phosphate dehydrogenase amplification was performed. The amplified fragments were stained with 0.3 mg/mL ethidium bromide (Sigma, St Louis, MO, USA) and detected by electrophoresis in 2% (w/v) agarose gel.

Cytogenetic analysis of BCWM.1 cells
Cytogenetic studies of BCWM.1 cells were performed using conventional GTG and both metaphase and interphase fluorescence in situ hybridization (FISH). FISH analyses were performed using the bacterial artificial chromosome probes RP11-79L7, RP11-91C23, RP11-171J20, which hybridize to 6q21, 6q21-22, and

Figure 1. Morphology of BCWM.1 cells discerned at 400× magnification following Giemsa staining under light microscopy (A) and under electron microscopy at 5000× (B) demonstrating typical features of lymphoplasmacytic cells.
6q22.1, respectively, and CEP6, which hybridizes to the centromere of chromosome 6 (Children’s Hospital Oakland Research Institute) as before [4]. One-hundred cells were counted, and detection of the 6q21-22 deletion was deemed to be positive when $\geq 5\%$ and $\geq 6\%$ of the cells showed loss of hybridization to RP11-91C23 and RP11171J20, and RP11-79L7, respectively [4].

Assessment of clonality by DNA fragment analysis of IgH V/D/J rearrangements

Genomic DNA from BCWM.1 cells was prepared by the Trizol method (Invitrogen) according to manufacturer’s instructions. Re-arranged IgH V/D/J segments were amplified from 20 to 80 µg genomic DNA template using 5’hexachloro-fluorescein phosphoramidite labeled FR1c (5’GGTGCAGCTG(G/C)(A/T)G(G/C)AGTC(G/A/T)GG3’) and JHc (5’ACCTGAGGAGACGGTACC(G/G)(G/T)G(T)TG3’) primers as before [11]. The PCR product was mixed with formamide and size standard (GeneScan-500, Applied Biosystems, Foster City, CA, USA), and then analyzed on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems) according to manufacturer’s instructions. Data analysis was performed using GeneMapper software version 3.5.

Gene array analysis of BCWM.1 cells

Total RNA was extracted from BCWM.1 cells and CD19+ selected mononuclear cells obtained from healthy donors using the RNeasy Mini Kit (Qiagen). Two to five micrograms extracted RNA were used to generate a cRNA probe by T7 transcription. Fragmented cRNA was then hybridized on human HG-U133 Plus 2 oligonucleotide probe arrays (Affymetrix, Santa Clara, CA, USA) for analysis of mRNA expression levels corresponding to 22,284 transcripts. Arrays were prepared and processed according to manufacturer’s directions. The arrays were scanned using the Gene Array scanner (Affymetrix), and the raw intensity. CEL files were normalized with R/Bioconductor software affy package. Bioconductor limma package was used to identify differentially expressed genes. Genes with fold change above 1.5 and $p$ value (multitest adjusted) $<5\%$ were chosen for further analysis, such as pathway enrichment and Gene Ontology classification analysis. All arrays were performed twice in independent experiments.

SNP array analysis

The extraction of genomic DNA from the founding patient’s sorted primary lymphoplasmytic cells and BCWM.1 cells was performed using QIAamp DNA Extraction Kit (Qiagen) according to manufacturer’s instructions. The Affymetrix gene chip mapping 500K array (Sty I and Nsp I arrays) was used according to manufacturer’s instructions at the Microarray Core Facility, Dana-Farber Cancer Institute, Harvard Medical School (Boston, MA, USA). SNP expression was analyzed with dChipSNP Software. Inferred chromosome copy number changed to 3 or 1 was considered a significant amplification or deletion.

In vivo engraftment of BCWM.1 cells in SCID-hu mice

Six- to eight-week-old male CB-17 SCID mice (Taconic, NY, USA) were housed and monitored in our Animal Research Facility. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee (VA Boston Healthcare System). Human fetal long bone grafts (SCID-hu) were implanted into SCID mouse as described previously [26]. Briefly, SCID mice were surgically implanted with human bone chips from fetal femurs or tibia obtained at 19 to 23 weeks gestation. Approximately 4 weeks after implantation, $2.75 \times 10^6$ BCWM.1 cells suspended in 50 µL phosphate-buffered saline were injected directly into human fetal bone implants within SCID-hu mice. Increasing levels of circulating human paraprotein in mice sera were used to monitor tumor engraftment and growth of BCWM.1 cells in SCID-hu mice. Peripheral blood from mice was serially collected from tail veins and serum tested for circulating human IgM, IgG, k and l light chain by enzyme-linked immunosorbent assay (ELISA; Bethyl Inc., Montgomery, TX, USA), as described previously [26]. ELISA kits used reacted specifically with human immunoglobulins, and did not cross-react with murine immunoglobulins. In some experiments, soluble CD27 was also assessed by ELISA (Bender Medsystems, Burlingame, CA, USA). Fetal bone chips and murine femurs were assessed for BCWM.1 engraftment by histological examination, and assessment by
immunohistochemistry by staining with antibodies for human CD20, IgM, IgG, IgA, κ and λ.

Assays for detection of human immunoglobulin and soluble CD27 secretion
In vitro supernatants from cultures of BCWM.1 cells and murine sera obtained from BCWM.1 engrafted SCIF-hu mice were evaluated by ELISA kits for detection of human IgM (Zeptometrix, Buffalo, NY, USA), human κ and λ light chains (Bethyl Inc., Montgomery, TX, USA), and soluble CD27 (Bender Medsystems).

Assessment for mycoplasma and Epstein Barr virus infection
BCWM.1 cells were evaluated for mycoplasma infection using a mycoplasma detection kit (Roche Diagnostics Corporation, IN, USA). BCWM.1 cells were also evaluated for Epstein-Barr virus infection by immunohistochemical staining (R&D Systems) and RT-PCR analysis for latent membrane protein 1.

Results

Growth and morphological characteristics of BCWM.1 cells
At an optimum concentration of 0.5–1.0 × 10^6 cells/mL, BCWM.1 cells demonstrated a doubling time of 3 days in RPMI medium supplemented with 10% fetal bovine serum, antibiotics and L-glutamine. BCWM.1 was morphologically characterized as a lymphoplasmacyte displaying prominent nucleoli and ample cytoplasm by Giemsa staining under 400× magnification by light microscopy (Fig. 1). By

Figure 3. Expression of BLyS, APRIL, and their receptors (BCMA, TACI, BAFF-R) by flow cytometric (A) and reverse transcriptase polymerase chain reaction analysis (B) in BCWM.1 cells.

Figure 4. Molecular analysis demonstrating clonality of BCWM.1 cells. Graph shows FR1c/JHc amplification of BCWM.1 genomic DNA analysis. The X-axis represents length of DNA fragment. The green bar is the amplified product demonstrating clonality using FR1c/JHc primers. Orange peaks represent DNA markers.
electron microscopy, the nucleus of BCWM.1 cells showed evenly dispersed chromatin with prominent nucleoli, abundant cytoplasm, organelles, and mitochondria and displayed both short and long profiles of rough endoplasmic reticulum at 5000× magnification (Fig. 1). BCWM.1 cells were positive for Epstein-Barr virus latent membrane protein 1 expression by immunohistochemistry and RT-PCR analysis, and negative for mycoplasma infection.

**Immunophenotypic characterization of BCWM.1 cells**

By flow cytometric analysis, BCWM.1 cells demonstrated the following immunophenotypic characteristics: CD3+, CD4+, CD5+, CD8+, CD9+, CD10+, CD11a+, CD11c+, CD14-, CD16+, CD19+, CD20+, CD22+, CD23+, CD25+, CD27+, CD30+, CD30L-, CD34-, CD38+, CD40+, CD154 (CD40L)+, CD45RA+, CD45RO+, CD52-, CD56+, CD66b-, CD70+, CD80+, CD103-, CD117+, CD138+, FMC7--; positive intracellular staining for cIgM+, cIgG, cIgA, κ+, λ+ (Fig. 2). BCWM.1 cells also expressed APRIL and B-Lymphocyte Stimulator, as well as the APRIL and BLYS receptors TACI, BCMA, and BAFF-R by flow cytometric and RT-PCR analysis (Fig. 3).

**Cytogenetic analysis**

Karyotype analysis demonstrated 46 chromosomes, XX, in BCWM.1 cells without cytogenetic anomalies (data not shown). By FISH analysis for the 6q21 deletion, 94 of 100 cells (94%) showed a hybridization pattern consistent with the presence of two copies of this chromosomal locus (data not shown). Greater than 10% of cells with the deletion is considered positive, as previously reported [4].

**Molecular analysis for FR1c/JHc amplification of genomic DNA**

Molecular analysis by FR1c/JHc amplification of genomic DNA using single-cell sorting demonstrated a consistent monoclonal peak, thereby establishing clonality for BCWM.1 cells (Fig. 4).

**Gene and SNP array analysis**

To understand the tumorgenesis mechanism of BCWM.1 cell line, Affymetrix GeneChip Hgu133Plus2 was employed to compare the gene expression profile between BCWM.1 cells (performed in independent duplicate experiments), the founding primary lymphoplasmacytic cells and B cells isolated from the bone marrow of four healthy donors. Genes with fold change > 1.5 and p value (multitest adjusted) ≤0.05 were considered significant and chosen for further analysis. As shown in Figure 5, gene expression profiling demonstrated considerable overlap between BCWM.1 and the founding patient’s primary lymphoplasmacytic cells. However, when BCWM.1 cells were compared by gene expression profiling to normal donor BM B cells for genes relevant in B-cell growth and signaling, 17 genes were significantly up- or downregulated as shown in Table 1. To detect any potential chromosome changes between BCWM.1 cell line and the founding primary lymphoplasmacytic cells, we also performed 500K SNP array hybridization and analysis. Inferred chromosome copy number change from dChipSNP software revealed a decrease in copy number (to 1) at chromosome 3p14.2 (chr3:60,097,950-60,762,791) when BCWM.1 cells were compared against the founder patient’s primary lymphoplasmacytic cells.

**In vivo engraftment in SCID-hu mice**

We next evaluated the engraftment ability of BCWM.1 cells in five SCID-hu mice by direct subcutaneous injection at 2.75 × 10^6 cells/mouse. After 30 weeks of observation,
no tumor growth occurred, and no human paraprotein was detectable in serum. We subsequently inoculated BCWM.1 at the same concentration in a fetal bone chip, which was implanted in five other SCID-hu mice. Human paraproteins were undetectable at baseline, but were readily detectable in four mice at 2 weeks, and in one mouse at 4 weeks. Importantly, follow-up evaluation at 4 weeks showed both increasing serum IgM and \( \lambda \)-light chain levels in all five mice (Table 2). In a separate pilot study, and under the same conditions, we implanted BCWM.1 inoculated fetal bone chips into five other SCID-hu mice in which both serum IgM and sCD27 levels were followed. Both serum IgM and sCD27 levels were undetectable at baseline, but became readily detectable at 2 weeks and continued to rise to 12 weeks (data not shown).

To ascertain the distribution of engraftment of BCWM.1 cells, as well as the necessity for a human bone marrow environment to support BCWM.1 engraftment, we performed a detailed histological examination of the human and mouse bone marrows by examining decalcified sections of the human fetal bone implanted bone chips and mouse femurs, as well as murine spleens, liver, lung, kidney, and lymph nodes from four SCID-hu mice following 4 weeks of BCWM.1 engraftment. Histological and immunohistochemical evaluation demonstrated the presence of diffuse lymphoplasmacytic cells in the human bone marrow (Fig. 6), but not murine bone marrow, spleen, liver, lung, or kidney (data not shown) which stained for human CD20, IgM, and \( \lambda \)-light chains but not human IgA, IgG, or \( \kappa \) light chains (Fig. 7).

**Discussion**

A significant impairment in understanding the biology and advancing novel therapeutics for WM has been the lack of a representative cell line and animal model. We, therefore, report on work accomplished in our laboratories in establishing the BCWM.1 cell line and a SCID-hu mouse model utilizing BCWM.1 cells to recapitulate the biology of WM.

As demonstrated in these studies, BCWM.1 bore the morphological, phenotypic, and genotypic properties of LPC typically found in WM, as well as important biological features, such as the secretion of IgM and sCD27 that serve as surrogate markers of disease in WM [20]. The production of sCD27 may particularly be significant for the pathogenesis of WM, since this ligand induces the growth and survival factors APRIL and CD40L on mast cells, which express the receptor for CD27 (CD70); are increased in number in the BM of patients with WM; and are usually found in close association with LPC [24]. Soluble CD27

### Table 1. Dysregulated genes involved in B-cell homeostasis by comparative gene expression profiling of BCWM.1 vs normal donor bone marrow B cells

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosomal locus</th>
<th>Function</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Downregulated</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin-6</td>
<td>7p21</td>
<td>B-cell differentiation</td>
<td>0.0003</td>
</tr>
<tr>
<td>syk</td>
<td>9q22</td>
<td>B-cell receptor-independent calcium-induced apoptosis</td>
<td>0.0018</td>
</tr>
<tr>
<td>Burkitt lymphoma receptor 1, GTP binding protein</td>
<td>11q23</td>
<td>B-cell migration</td>
<td>0.0054</td>
</tr>
<tr>
<td>fyn</td>
<td>6q21</td>
<td>Src family tyrosine kinase</td>
<td>0.0124</td>
</tr>
<tr>
<td>( \zeta )-chain (TCR) associated protein kinase</td>
<td>2q12</td>
<td>IgM signaling</td>
<td>0.0134</td>
</tr>
<tr>
<td>Phospholipase C, ( \beta )</td>
<td>15q15</td>
<td>PKC-catalyzed phosphorylation</td>
<td>0.0162</td>
</tr>
<tr>
<td>Rho guanine nucleotide exchange factor (GEF) 1</td>
<td>19q13</td>
<td>Erk and PI-3 kinase pathway</td>
<td>0.0267</td>
</tr>
<tr>
<td>lef-1</td>
<td>4q23</td>
<td>Wnt signaling, B-cell development</td>
<td>0.0361</td>
</tr>
<tr>
<td><strong>Upregulated</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fas (CD95)</td>
<td>10q24</td>
<td>Programmed cell death</td>
<td>0.0018</td>
</tr>
<tr>
<td>CASP8 and FADD-like apoptosis regulator</td>
<td>2q33</td>
<td>Programmed cell death</td>
<td>0.0018</td>
</tr>
<tr>
<td>Calnexin</td>
<td>5q35</td>
<td>Protein folding and assembly</td>
<td>0.0134</td>
</tr>
<tr>
<td>Mitogen-activated protein kinase 7</td>
<td>17p11</td>
<td>TNFR1 signaling pathway</td>
<td>0.0188</td>
</tr>
<tr>
<td>p21 (CDKN1A)- activated kinase 2</td>
<td>3q29</td>
<td>Regulation of B-cell proliferation</td>
<td>0.0188</td>
</tr>
<tr>
<td>Eukaryotic translation initiation factor 2, subunit 1 ( \alpha )</td>
<td>14q23</td>
<td>Protein synthesis initiation</td>
<td>0.0205</td>
</tr>
<tr>
<td>Caspase-1, apoptosis-related cysteine protease</td>
<td>11q23</td>
<td>Programmed cell death</td>
<td>0.0258</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mouse Code</th>
<th>Isotype</th>
<th>Cells ((x10^6))</th>
<th>Weeks to IgM detection</th>
<th>Level of IgM ((\mu g/mL))</th>
<th>Level of IgM ((\mu g/mL))</th>
<th>Level of ( \lambda )-light chain ((\mu g/mL))</th>
<th>Level of ( \lambda )-light chain ((\mu g/mL))</th>
</tr>
</thead>
<tbody>
<tr>
<td>680D</td>
<td>IgM ( \lambda )</td>
<td>2.75</td>
<td>2</td>
<td>9.1</td>
<td>20.1</td>
<td>9.4</td>
<td>23.6</td>
</tr>
<tr>
<td>323B</td>
<td>IgM ( \lambda )</td>
<td>2.75</td>
<td>4</td>
<td>0</td>
<td>12.4</td>
<td>4.6</td>
<td>10.3</td>
</tr>
<tr>
<td>NA</td>
<td>IgM ( \lambda )</td>
<td>2.75</td>
<td>2</td>
<td>54.4</td>
<td>152.6</td>
<td>57.5</td>
<td>114.2</td>
</tr>
<tr>
<td>072D</td>
<td>IgM ( \lambda )</td>
<td>2.75</td>
<td>2</td>
<td>153.7</td>
<td>381.3</td>
<td>115.4</td>
<td>227.2</td>
</tr>
<tr>
<td>2D36</td>
<td>IgM ( \lambda )</td>
<td>2.75</td>
<td>2</td>
<td>20.16</td>
<td>50.4</td>
<td>16.8</td>
<td>35.2</td>
</tr>
</tbody>
</table>

**Table 2.** Serial paraprotein measurements in SCID-hu mice engrafted with BCWM.1 WM cells
may also have other important roles in WM pathogenesis, including immune suppression [27].

BCWM.1 cells also expressed APRIL and BLYS, as well as their receptors TACI and BCMA (for both APRIL and BLYS) and BAFF-R (for BLYS). Similar findings have been reported by us and others in primary WM LPC [17,18], as well as on malignant cells in other B-cell disorders [28,29]. The expression of both APRIL and BLYS as well as their receptors on WM cells may have important roles in WM pathogenesis, particularly because these ligand-receptor pathways have well-defined roles in LPC differentiation and IgH class switching. The BCWM.1 cell line may therefore provide a convenient model for the regulatory study of APRIL and BLYS in WM.

As part of these studies, we also performed extensive cytogenetic, molecular, and gene expression studies on BCWM.1 cells. These studies confirmed the clonality of BCWM.1 cells by determination of IgH rearrangements through FR1c/JHc amplification of genomic DNA, while SNP-1 analysis demonstrated close propinquity of BCWM.1 cells to the founder patient’s primary LPC, with the sole change being an decrease (to one) in copy number at 3p14.2. Two potential genes of interest at 3p14.2 are the fragile histidine triad gene (FHIT) and the protein tyrosine phosphatase receptor type G gene, both of which are candidate tumor suppressor genes [30]. Aberrant expression of FHIT has been reported in several B-cell malignancies [31,32], and further investigation of both the FHIT and phosphatase receptor type G genes in the pathogenesis and progression of WM would appear warranted. Interestingly, gene expression profiling revealed significant differences in 17 genes with a role in B-cell homeostasis that are worthy of further study in WM, including fyn, which is located at 6q21, a site shown by us and others to be frequently deleted in patients with WM, and which may have a role in the progression of IgM MGUS to WM [4–6].

As is typical of primary LPC from most WM patients, no gross structural abnormalities were found in BCWM.1 cells by karyotype and multicolor fluorescence in situ.

---

**Figure 6.** Histological analysis for human bone marrow engraftment in severe combined immunodeficient (SCID)-hu mice with BCWM.1 lymphoplasma-cytic cells. Histological analysis was performed on decalcified fetal bone chips implanted in SCID-hu mice following engraftment with BCWM.1 lymphoplasma-cytic cells. Bone chips were retrieved from SCID-hu mice at 12 weeks following serial detection of rising human paraproteins in murine serum. Fetal bone chips were then stained with hematoxylin and eosin, and viewed under light microscopy at 100× (1), 400× (2), and 200× (3).
hybridization studies. However, a vast number of upregulated (n = 5,409) and downregulated (n = 3,155) genes between BCWM.1 cells and normal donor bone marrow B cells were observed. These differences might reflect epigenetic changes resulting from transforming events, or the differentiation (i.e., lymphoplasmacytic) state of WM cells relative to normal donor BM B cells. Further studies, particularly of genes detected in aberrant B-cell signaling pathways (as described in Table 1) may provide informative clues behind the transforming events in WM.

An important characteristic of BCWM.1 cells is their rapid engraftment in the SCID-hu mice. As with primary WM LPC [26], BCWM.1 cells also required the human BM milieu for their growth and expansion since subcutaneous injection of BCWM.1 cells in SCID mice failed to lead to engraftment. Human serum IgM and λ light chain, as well as soluble CD27, a novel tumor marker for WM [19,20], were readily detectable following engraftment of BCWM.1 cells. The potential use of BCWM.1 engrafted SCID-hu mice as a relevant model for the study of novel WM therapeutics was recently demonstrated by us using the CD70-directed monoclonal antibody SGN-70. BCWM.1 engrafted SCID-hu mice responded to SGN-70 therapy, whereas untreated mice demonstrated continued disease progression [20].

In summary, the BCWM.1 cell line provides a disease appropriate cell system for the study of WM, which in conjunction with the SCID-hu mouse model may be used as a convenient model for studies focused on both WM pathogenesis and development of targeted therapies for WM.

**Acknowledgments**
The authors wish to acknowledge and thank John Daley and Susan Lazo at the Dana-Farber Cancer Institute for their help with flow cytometric analysis and cell sorting; Courtney Hyland, Charles Lee and Cynthia Morton from the Cytogenetics Core of Dana-Farber /Harvard Cancer Center; Dr. Maria Ericsson from the Electron Microscopy Core Facility at Harvard Medical School; Drs. Edward Fox, Sigitas Jonas Verselis, Changzhong Chen and Maura A. Berkeley from the Microarray Core Facility at the Dana-Farber/ Harvard Cancer Center.


**References**


